Production (Stage)
CytomX Therapeutics, Inc.
CTMX
$2.68
-$0.07-2.55%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 41.60M | 31.87M | 13.83M | 11.09M | 16.53M |
| Total Depreciation and Amortization | 1.69M | 1.77M | 1.84M | 1.90M | 2.05M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.16M | 6.55M | 5.58M | 4.01M | 4.12M |
| Change in Net Operating Assets | -132.67M | -126.42M | -109.53M | -102.79M | -114.13M |
| Cash from Operations | -81.23M | -86.23M | -88.29M | -85.80M | -91.43M |
| Capital Expenditure | -314.00K | -310.00K | -496.00K | -486.00K | -907.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 85.73M | 100.01M | 97.93M | 36.81M | 41.76M |
| Cash from Investing | 85.41M | 99.70M | 97.43M | 36.33M | 40.85M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 7.35M | 7.52M | 5.52M | 5.52M | 735.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00 | 29.67M | 29.67M |
| Cash from Financing | 7.35M | 7.52M | 5.52M | 35.19M | 30.40M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 11.53M | 20.99M | 14.66M | -14.29M | -20.17M |